These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 31391106)

  • 1. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
    Xu R; Wang Q
    J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
    Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
    Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
    Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
    Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
    Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
    Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection.
    Xu R; Wang Q
    BMC Bioinformatics; 2014 Jan; 15():17. PubMed ID: 24428898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing Deep Learning for Detecting Adverse Drug Events in Structured and Unstructured Regulatory Drug Data Sets.
    Knisely BM; Hatim Q; Vaughn-Cooke M
    Pharmaceut Med; 2022 Oct; 36(5):307-317. PubMed ID: 35871475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Different Adverse Effects Among Multiple Drugs Using FAERS Data.
    Huang J; Zhang X; Du J; Duan R; Yang L; Moore JH; Chen Y; Tao C
    Stud Health Technol Inform; 2017; 245():1268. PubMed ID: 29295353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.
    Alsuhibani A; Alrasheed M; Gari M; Hincapie AL; Guo JJ
    Int J Clin Pharm; 2022 Feb; 44(1):172-179. PubMed ID: 34564826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.